GLP-1 insurance coverage: Why the $50 Medicare bridge is a mixed bag

Access to GLP-1 medications is currently undergoing a strange bifurcation. While some groups see their options widen and costs drop, others are seeing their coverage vanish entirely. PepsiCo, Starbucks, and Cigna have recently dropped weight loss drug coverage for employees due to rising costs. Simultaneously, Medicare has introduced a bridge program that caps the monthly cost of these drugs at $50. The result is a paradox where a 65-year-old on Medicare may find it easier to afford their medication than a 40-year-old with a robust private plan.

Determining your insurance coverage for GLP-1 medications is no longer a simple binary choice. It depends heavily on your age, your specific diagnosis, and which version of Medicare you enrolled in. The landscape is a tangled web of exclusions, medical necessity requirements, and temporary subsidies. These factors create a system that favors certain patient groups while leaving others to navigate a patchwork of restrictions and temporary fixes.

The Private Insurance Squeeze

Private insurers are pulling back hard. PepsiCo informed its staff that weight loss drugs had become one of the fastest-growing cost drivers in their plans. Consequently, they removed coverage for weight management, retaining it only for diabetes. Starbucks ended coverage for eligible employees in October, while Cigna made similar cuts in July. This shift is significant because many workers relied on employer plans to afford these expensive medications, which can cost thousands of dollars per month out of pocket.

For those losing this employer-sponsored coverage, the financial hit is immediate and steep. Unlike Medicare, which now has a specific bridge for weight loss, private plans typically require a diagnosis like type 2 diabetes to cover the drug. If your prescription is solely for weight management, you are likely looking at cash prices or discount cards. These costs vary widely by pharmacy and location, making budgeting difficult for many.

Medicare Advantage vs. Original Medicare

The comparison between Medicare options is often misunderstood. Original Medicare does not cover prescription drugs at all. You need Part D or a Medicare Advantage plan to get any drug coverage. Medicare Advantage plans are private plans that bundle medical and drug benefits, and they are bound by the same rules as Part D regarding what can be covered. The distinction is not really about which Medicare version you have, but about the specific rules of the plan you choose during open enrollment.

The bridge program, however, is a federal initiative that applies to eligible Medicare beneficiaries regardless of whether they are in a standalone Part D plan or a Medicare Advantage plan. This means the $50 monthly option for weight loss should be available to both groups, provided they meet the eligibility criteria. The main difference will be in how the plan handles prior authorization and formulary tiers for other medical conditions that do qualify for standard coverage.

The Diagnosis Gatekeeper

A 2003 federal law bars Part D from covering drugs prescribed for weight loss alone. This is the key constraint that separates standard coverage from the bridge program. Under standard rules, Medicare will cover Wegovy if you have established heart disease and are overweight or obese. It will cover Zepbound if you have moderate-to-severe obstructive sleep apnea and obesity. These are specific medical indications, not general wellness benefits.

If you do not have one of these qualifying diagnoses, you fall into the bridge program category. This program was launched by CMS in July 2026 and extended through December 2027. It offers a flat $50 monthly cost for weight loss medications. This is a massive reduction compared to list prices, but it is a temporary measure. Once the bridge program ends, those without a qualifying diagnosis will face the full cost of the medication or seek alternative coverage.

Who Is Most Affected by the Bridge

The bridge program acts as a lifeline for those who lose employer coverage at age 65. Consider a hypothetical 65-year-old who was on Zepbound for weight loss and loses their PepsiCo or Starbucks plan. They transition to Medicare during open enrollment, which runs from October 15 to December 7. Without the bridge program, they would have to pay full price or switch to a drug not covered for weight loss. With the bridge, they pay $50 a month.

However, this benefit is not universal. It is specifically for weight management. If you have diabetes, you are already covered under standard Part D rules, so the bridge program is less critical for you. The bridge is primarily for the millions of older Americans who use these drugs for obesity but do not have a comorbidity that triggers standard coverage. This group is the most vulnerable to the recent employer cuts.

Out of Pocket Limits and 2027 Changes

Even with the bridge program, there are out of pocket costs to consider. For standard Part D coverage, the out of pocket threshold rises to $2,400 in 2027, up from $2,100 in 2026. The maximum deductible also climbs to $700 from $615. Once you hit the threshold, you pay nothing for covered drugs for the rest of the year. This cap provides significant protection for those who qualify for standard coverage, but it does not apply to the $50 bridge program, which is a separate, fixed cost.

The bridge program is a stopgap. CMS extended it through December 2027, but that is not a permanent solution. Patients relying on this $50 option need to understand that it is a temporary relief. The long term stability of their coverage depends on whether Congress extends the program or if drug manufacturers and insurers find a permanent way to share the cost. For now, the $50 price tag is a clear win, but the clock is ticking.